Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice.

Stewart, C F; Zamboni, W C; Crom, W R; Houghton, P J

Stewart, C F; Zamboni, W C; Crom, W R; Houghton, P J.

Affiliation

Stewart CF; Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN 38101-0318, USA.

Cancer Chemother Pharmacol ; 40(3): 259-65, 1997.

Article in En | MEDLINE | ID: mdl-9219511

Subject(s)

Antineoplastic Agents, Phytogenic/pharmacokinetics; Camptothecin/analogs & derivatives; Administration, Oral; Animals; Antineoplastic Agents, Phytogenic/administration & dosage; Area Under Curve; Blood Proteins/metabolism; Camptothecin/administration & dosage; Camptothecin/pharmacokinetics; Female; Injections, Intravenous; Irinotecan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Neuroblastoma; Protein Binding

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Camptothecin / Antineoplastic Agents, Phytogenic Type of study: Prognostic_studies Limits: Animals Language: En Journal: Cancer Chemother Pharmacol Year: 1997 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links